Literature DB >> 26065144

What stops people completing multi-drug therapy? Ranked perspectives of people with leprosy, their head of family and neighbours--across four Indian states.

M S Raju, Annamma S John, Pim Kuipers.   

Abstract

UNLABELLED: Summary To maximise successful completion of multi-drug therapy (MDT) and optimise treatment outcomes for people with leprosy, it is vital to understand the relative importance of perceived factors which prevent them from completing the required number of doses in time.
OBJECTIVE: To explore personal, family, social, community, attitudinal, practical, geographical, cultural and traditional factors which may influence adherence to treatment, a two-phase study was undertaken comprising issue identification via focus groups, and a ranking exercise via individual interview. STUDY
DESIGN: The perspectives of 895 respondents (320 people affected by leprosy who were not able to complete treatment, 302 of their 'operational heads of family', and 273 of their nearby community members) across four states of India namely i.e. Andhra Pradesh (Salur), Chhattisgarh (Chandkhuri), Maharashtra (Kothara) and Uttar Pradesh (Barabanki) were collected, using a checklist interview method.
RESULTS: Findings suggest that seeing positive changes in their symptoms as well as not seeing improvement can lead to non-completion of MDT. Problems with scheduling and travel expenses were also key issues. Better management of the expectations of people affected by leprosy and reducing the burden of treatment may be important strategies. The importance of stigma and poverty were noted through a number of issues, none of which were particularly highly ranked.
CONCLUSIONS: The nature and diversity of perceived issues identified across respondent type and particularly region, suggest that the determinants of adherence are complex and multi-factorial. More community based approaches with greater coordination at the community level are recommended.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26065144

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  5 in total

Review 1.  Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.

Authors:  Malcolm S Duthie; Marivic F Balagon
Journal:  Risk Manag Healthc Policy       Date:  2016-04-27

2.  A comprehensive research agenda for zero leprosy.

Authors:  Peter Steinmann; Courtenay Dusenbury; David Addiss; Fareed Mirza; W Cairns S Smith
Journal:  Infect Dis Poverty       Date:  2020-11-12       Impact factor: 4.520

Review 3.  A Literature Review: The History of Psychological Impact of Illness amongst People with Leprosy (PwL) in Countries across the Globe.

Authors:  Pati Aji Achdiat; Eko Fuji Ariyanto; Michael Nobel Simanjuntak
Journal:  Dermatol Res Pract       Date:  2021-11-09

4.  Nitazoxanide is active against Mycobacterium leprae.

Authors:  Mai Ann Bailey; Hana Na; Malcolm S Duthie; Thomas P Gillis; Ramanuj Lahiri; Tanya Parish
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

5.  The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.

Authors:  Yang Liu; Yamin Gao; Jianxiong Liu; Yaoju Tan; Zhiyong Liu; Chiranjibi Chhotaray; Huofeng Jiang; Zhili Lu; Gift Chiwala; Shuai Wang; Gaelle Makafe; Md Mahmudul Islam; H M Adnan Hameed; Xingshan Cai; Changwei Wang; Xinjie Li; Shouyong Tan; Tianyu Zhang
Journal:  Nat Commun       Date:  2019-01-31       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.